Organization · Venture Capital
LifeLink Ventures
LifeLink Ventures is an early-stage investment firm based in Barcelona, Spain, specializing in biotech and health companies. The firm connects private investors with innovative companies addressing global health challenges.
Overview
What LifeLink Ventures does
What LifeLink Ventures is
LifeLink Ventures is an early-stage investment firm based in Barcelona, Spain, specializing in biotech and health companies. The firm connects private investors with innovative companies addressing global health challenges.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2020
- Approximate age
- About 6 years
- Structured capabilities
- Funder
- Last reviewed
- April 9, 2026
Official channels
Find LifeLink Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
LifeLink Ventures as a funder
Investment thesis
LifeLink Ventures bridges private capital with innovative life sciences opportunities, focusing on companies addressing global health challenges.
Focus narrative
LifeLink Ventures primarily invests in early-stage health and biotech companies across Europe and the United States. The firm seeks to partner with companies that are developing differentiated therapies for challenging health conditions. Their investment approach is flexible, allowing for a range of ticket sizes and follow-on investments, ensuring they can support their portfolio companies effectively.
Value beyond capital
LifeLink Ventures adds value to its portfolio companies through data-driven due diligence grounded in scientific expertise. The firm emphasizes building long-term relationships with founders, providing not just capital but also strategic guidance and support to help navigate the complexities of the biotech landscape.
Terms and economics
- Sweet spot
- $47,500,000
Focus and fit
- Stages
- Pre-seed · Seed · Seed+ · Series A · Series B
- Regions
- EuropeNorth America
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 12
Portfolio context
Notable portfolio companies include: Crossbow Therapeutics: Develops next-generation antibody therapies in oncology (USA). Haya Therapeutics: Focuses on RNA-guided therapies for cardiometabolic diseases (Switzerland). Arda Therapeutics: Works on cell depleting therapies for fibrotic diseases (USA). AiRNA: Develops disruptive RNA editing therapies (USA). Immunitas Therapeutics: Engaged in clinical stage precision immunotherapy for cancer (USA). InCephalo Therapeutics: Focuses on next-generation CNS cancer drugs (Switzerland). Ochre Bio: Develops RNA therapeutics for liver disease (UK). Macomics: Works on reprogramming macrophages for cancer treatment (Scotland). Eveliqure: Develops the first shigella and ETEC vaccine (Austria). Spiral Therapeutics: Focuses on therapies for hearing loss (USA). Doctify: A healthcare review platform (UK). Accure: Develops new drugs for CNS disorders (Spain).
Common questions
What to know about LifeLink Ventures
Upseed classifies LifeLink Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
April 9, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.